The first studies that reported on the prevalence of RI in cancer patients were the "IRMA studies" (Insuffisance Ré-
nale et Médicaments Anticancéreux -Renal Insufficiency and Anticancer Medications). These two cohorts included about 10,000 adult cancer patients with solid tumors (mainly breast, colorectal, and lung). Approximately half of them were nonmetastatic at the time of inclusion, and not on dialysis (1, 2) . In these cohorts, 52.9% and 50.2% of the patients in IRMA-1 and IRMA-2, respectively, had a reduced eGFR (lower than 90 mL/min/1.73 m²), and 12.0% and 11.8% had stage 3 or 4 RI (lower than 60 mL/min/1.73 m²). Interestingly, cancer patients rarely present with a normal eGFR. Several other studies have reported on the prevalence of RI in cancer patients. For instance, in patients with kidney cancer, Huang et al (3) reported a particularly high (87%) prevalence of abnormal renal function (lower than 90 mL/min/1.73 m²) in a cohort of 662 patients with a renal cortical tumor (<4 cm) awaiting partial or radical nephrectomy. The prevalence of an eGFR lower than 60 mL/min/1.73 m² was also higher than the one reported in the IRMA studies, with 26% of the patients with at stage 3-4 RI. Other studies in Belgium (4), the USA (5), Japan (6) , and Austria (7) reported the prevalence of an eGFR <60 mL/min/1.73 m 2 of 16.1%, 22.0%, 25.0%, and 14.7 to 16.1%, respectively.
In the IRMA-2 study, the potential impact of RI on patient survival had been assessed through a 2-year follow-up. The results showed that patients with an eGFR lower than 60 mL/min/1.73 m² at the time of inclusion in the study had a significantly lower survival rate compared to patients with an eGFR greater than or equal to 60 mL/min/1.73 m². Considering the 2,382 patients who had a nonmetastatic disease, the impact of RI on survival was still significant. The survival was 21.0 vs. 25.0 months for patients with an eGFR lower than or equal to 60 mL/min/1.73 m², respectively.
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Introduction
Over the past 10 years, increasing evidence has shown that renal insufficiency (RI) frequently occurs in cancer patients, especially in those presenting with solid tumors. More recent data have revealed the link between RI and reduced overall survival, while other studies have shown an association between RI and increased cancer-related mortality. Handling anticancer drugs in patients with a reduced estimated glomerular filtration rate (eGFR) is also an issue, which raises the question of drug dosage adjustment. As a result, looking after patients with cancer and RI requires specific attitudes and competencies to provide optimal therapeutic and clinical care.
Several issues warrant the tight and pro-active collaboration between nephrologists, oncologists, and other specialists, which is the ultimate aim of onco-nephrology as a novel subspecialty.
Hazard ratios (95% confidence interval) were 1.27 (1.12-1.44) and 1.43 (1.17-1.72) for the whole population and the nonmetastatic population only, respectively.
Recently, 2 studies showed the importance of anticancer drugs' dosage adjustments in those patients with an eGFR lower than 60 mL/min/1.73 m 2 . In the first study, Chen et al included 143 patients with metastatic colorectal cancer (mCRC) (8) . All the patients had normal serum creatinine at inclusion and were all treated with the same chemotherapy in terms of anticancer agents and drugs' dosage. After treatment, the renal function was estimated, and the patients were grouped depending on whether they had, at inclusion, a renal function lower or greater than 60 mL/min/1.73 m 2 . Safety and survival (time to progression) were compared between groups. Patients with RI experienced statistically significantly higher rates of doserelated adverse events, which led to significant rates of treatment discontinuation or interruption, and significantly reduced the time to progression. In another study in elderly patients with early breast cancer, Lichtman et al screened for RI in 619 patients who were then treated at dosages adjusted to their level of renal function, when dose reduction was required (9) . When the group of patients with an eGFR lower than 60 mL/min/1.73 m 2 (treated at adjusted doses) was compared to the group of patients with an eGFR greater than 60 mL/min/1.73 m 2 (treated at usual doses), there was no significant effect of RI on relapse-free survival or overall survival. These two studies emphasized the importance of adjusting the dosages of anticancer drugs to renal function when patients have RI.
screening for RI in cancer patients
Measuring eGFR with a gold-standard, isotopic method, such as 51 Cr-EDTA, in all cancer patients is unrealistic. As a result (e.g., in the general population), it is recommended that the eGFR be estimated from the serum creatinine, with validated formulae. For decades, the Cockcroft-Gault (CG) formula (10) has been the most frequently used formula. One major drawback is that the CG formula estimates the creatinine clearance (CrCl) and not the eGFR. The CG formula is no longer recommended, and should not be used. Two other equations have been released. The first, the Modification of the Diet in Renal Disease equation, under its abbreviated formulation with 4 variables (MDRD), is still recommended for eGFR estimation (11) . Currently, the more recent Chronic Kidney Disease -Epidemiology Collaboration (CKD-EPI) equation is the method of choice for estimating eGFR, and for the screening and diagnosis of RI. Furthermore, in some recent studies specifically conducted in patients with cancer, the MDRD equation confirmed its better precision compared to the CG formula in those patients (12) . It has been recommended that cancer patients' renal function be estimated with the MDRD formula, even in elderly cancer patients (13, 14) . However, data are still lacking on the performance of CKD-EPI collaboration equation specifically in cancer patients.
Once the estimation of renal function has been performed, the US National Kidney Foundation (KDOQI -Kidney Disease Outcomes Quality Initiative) (15) and the international working group KDIGO (Kidney Disease: Improving Global Outcomes) (16) have defined and stratified the severity of chronic RI, which applies also to cancer patients.
Understanding the mechanisms of the nephrotoxicity of novel anticancer agents
A number of anticancer agents may directly or indirectly affect the kidneys. While the nephrotoxicity associated with traditional cytotoxic agents (e.g., cisplatin) is well characterized, the recent development of a large number of molecularly targeted agents and of immune checkpoint inhibitors has dramatically widened the spectrum of adverse renal events. Indeed, like opening Pandora's Box, a wide array of previously unrecognized and ill-defined abnormalities of kidney function, such as hypertension, proteinuria, acute interstitial nephritis, thrombotic microangiopathy, and various electrolyte/acid-base disorders, are increasingly being observed with these novel agents. Once again, this highlights the need for specially trained clinicians with specific knowledge of these complications who can treat patients receiving these drugs (17) .
This knowledge should also lead us to preventively identify patients at risk, without necessarily waiting for the occurrence of renal impairment. Furthermore, we should check for nephrotoxicity throughout the whole development of oncological drugs, from phase I trials to postmarketing phase IV studies (17) .
taking care of patients with CKD or those on dialysis and overcoming the nihilistic approach that usually surrounds them
Preexisting CKD, in some instances, may disturb the bioavailability and/or safety profile of certain oncological drugs, and potentially lead to suboptimal treatments, or enhance the risk for drug-induced de novo kidney injury or the worsening of CKD. Some very effective anticancer agents may be avoided as a potential option in CKD patients due to the lack of specific information on their pharmacokinetic properties in this setting (18) .
As a consequence, therapeutic drug monitoring in cancer patients with CKD, especially in an advanced stage-or in the case of an overt end-stage renal disease (ESRD)-is of the utmost importance if and when active oncological treatment is started.
The growing prevalence of cancer and acute kidney injury (AKI) or CKD implies that an increasing number of patients will require the expertise of an onco-nephrologist, who must be knowledgeable about the vast array of anticancer agents, their pharmacokinetics in patients with CKD, and their potential toxic effects on kidney function (19) .
One of the more challenging areas of onco-nephrology is the appropriate management of cancer patients that require renal replacement therapy (RRT) for either AKI or ESRD-a patient population characterized by low survival rates. Decisions about anticancer drug choices and dosing are not often supported by pharmacokinetic or pharmacodynamic data, making therapeutic decisions difficult. Where data are available, the nephrologist should be well versed in the effects of the various dialytic modalities on drug clearance. A basic understanding of the effects of continuous RRT/hemodialysis/peritoneal dialysis on general drug clearance (volume of distribution, protein binding, molecular size, etc.) will allow reasonable estimates of the safety of anticancer drug dosing in such patients. Knowledge of anticancer drug interactions with other prescribed medications is also critical. Furthermore, the decision to initiate RRT or not in a cancer patient with ESRD remains a major ethical issue, which is best resolved by taking into account the prognosis (in terms of life expectancy), quality of life, and the wishes of the patient and his/her family (19) .
transplanted patients: where does the risk come from?
Another setting that requires a close working relationship between the nephrologist and oncologist is in the evaluation for transplantation of an ESRD patient with a previously treated malignancy. The question of how long to wait before placing such an ESRD patient on the transplantation list can be difficult. What is a sufficient length of time to consider a patient as cured, able to receive a graft, and undergo immunosuppression therapy? Even more complex is dealing with the flip-side of this issue. Is the patient with a previously treated malignancy a suitable kidney donor? In such a scenario, are all malignancies considered the same in this regard? Furthermore, if the patient is considered a suitable candidate, how much time should have elapsed from the original cancer diagnosis? Currently, none of these questions has a clear-cut or evidence-based answer. Obviously, while such data are sorely needed, expert opinion and experience from the onco-nephrology collaboration is the next best option.
Similarly, ESRD patients on the transplant waiting list have a higher incidence and prevalence of cancer compared with the general population, and therefore require cancer monitoring to avoid transplantation in the setting of malignancy.
Cancer is observed with increasing frequency in kidney transplant recipients receiving long-term immunosuppression. Management can be difficult and complicated by balancing the treatment of the malignancy with the maintenance of a functioning kidney (20) .
the need to design prospective studies in the field of onco-nephrology
As we move the field of onco-nephrology forward, it is imperative that our group begins to design and conduct randomized, controlled clinical trials (and other trial designs) aimed at addressing many of the issues and questions raised here. Only then can we provide evidence-based care to this complicated group of patients and ultimately improve their outcomes.
Identification and molecular classification of our target patients
Patients harboring defects in the DNA mismatch repair are known to be at a high risk for Lynch syndrome (21) or of neoplasms induced by physical and chemical carcinogens (e.g., melanomas in subjects exposed to UV rays) (22, 23) ; similarly, these genetic defects might predispose the patient to higher renal toxicities from anticancer agents, such as platinum derivatives.
This hypothesis should be confirmed formally, although the cost effectiveness of such tests should also be verified.
the need for a larger participation of nephrologists in the design of oncological trials
The relationships between oncological targeted agents and their effects on the kidneys are unexplored, or have very little available data, for several reasons: (i) the selection bias of randomized, controlled, phase III trials means that patients are enrolled only if they have conserved organ function; (ii) the interpretation of the real nature and incidence of renal adverse events from these trials is difficult because whether and how renal toxicity is assessed is often unclear; (iii) the terminology is not used in a standard way (e.g., the simplistic definition of "creatinine increase" makes no sense at all); and (iv) the definitions of CKD, the summaries of product characteristics, and the nephrological classifications (e.g., creatinine clearance and calculations of eGFR) are not uniformly applied across oncological trials (19) .
Another key point is to identify and correctly characterize meaningful renal endpoints, or develop tools/knowledge that are easily accessible for oncologists, so they can screen cancer patients for renal problems. Nephrologists cannot follow all cancer patients, so oncologists should be given some basic skills; for example, how to estimate eGFR, what it means, how to adjust anticancer drugs' dosages to renal function, and how to monitor for renal safety (19) .
Regulatory issues
The European Medicines Agency (EMA) recently issued an updated version of their guidelines to the industry on when and how to conduct specific trials in patients with RI. The full recommendation can be downloaded from the EMA website (24) and has been officially applicable since July 1, 2016. These guidelines emphasize that such studies should be conducted for drugs whatever their elimination pathway, including drugs that are hepatically metabolized, since (i) RI can also impair liver function in terms of drug metabolism; and (ii) hepatic metabolites can be excreted via the renal route, which can be impaired in patients with RI. The guidelines also provide practical recommendations, so studies can share a common methodology and provide the same level of information for clinical use. Due to the high prevalence of RI reported in cancer patients, such studies should be conducted in every new drug developed in the field of cancer. This should be considered as mandatory. In addition, new studies are needed for existing drugs.
These are the main reasons why we launched into this project with both enthusiasm and curiosity. This new journal aims to become a reference point for all those who, like us, think that a multidisciplinary approach and the sharing of a huge numbers of small pieces of experience could contribute to the development of onco-nephrology, with the ultimate aim of improving the outcomes of our nephropathic cancer patients.
